Skip to main content
. 2022 Mar;43(3):381–387. doi: 10.3174/ajnr.A7412

Table 1:

Patient demographics and comorbidities

Patient Characteristics (No.) (%)a IOCM (n = 4042) LOCM (n = 38,130)
Age (yr)
 Mean (SD) 69.1 (13.8) 67.2 (14.6)
Sex
 Male 2083 (51.5) 20,140 (52.8)
 Female 1959 (48.5) 17,988 (47.2)
Race
 White 3058 (75.7) 28,995 (76.0)
 Black 501 (12.4) 4652 (12.2)
 Other 483 (11.9) 4483 (11.8)
Insurance
 Commercial 174 (4.3) 2020 (5.3)
 Medicare 2619 (64.8) 22,347 (58.6)
 Medicaid 334 (8.3) 3907 (10.2)
 Managed care 670 (16.6) 6726 (17.6)
 Other 245 (6.1) 3130 (8.2)
Elixhauser Comorbidity Index scoreb  
 Mean (SD) 4.6 (2.2) 4.5 (2.2)
Chronic kidney disease        
 Stage 1 6 (0.1) 34 (0.1)
 Stage 2 33 (0.8) 319 (0.8)
 Stage 3 363 (9.0) 2067 (5.4)
 Stage 4 81 (2.0) 293 (0.8)
 Unspecified 274 (6.8) 1574 (4.1)
Record of acute kidney injury
 On admission 405 (10.0) 2929 (7.7)
 In previous admission 37 (0.9) 321 (0.8)
a

All values reported as No. (%) unless otherwise noted.

b

The Elixhauser Comorbidity Index score is calculated using 31 categories of comorbidities associated with mortality and is based on International Classification of Diseases 9 and 10 codes. Each comorbidity category is dichotomous and includes heart failure, cardiac arrhythmia, hypertension, diabetes mellitus, obesity, and so forth.